GSK, Innoviva’s Trelegy Ellipta meets primary endpoint in phase III asthma study

This article was originally published here

Trelegy Ellipta is a once-daily single inhaler triple therapy, which includes fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI). Fluticasone is an inhaled corticosteroid, while umeclidinium is a

The post GSK, Innoviva’s Trelegy Ellipta meets primary endpoint in phase III asthma study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply